 VERO BEACH, FL ACCESSWIRE June 15, 2021 Nascent Biotech, Inc. OTCQB:NBIO Nascent Biotech, Nascent, or the Company, a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to highlight the publication of an in-depth analyst research report on Nascent Biotech by equity research firm, Marble Arch Research, Inc, which rated NBIO a Speculative Buy under its tiered rating system, and specified a price target of between 0.39-1.99. The full research report may be found at: The report concludes, We believe that there is a reasonable investment thesis at hand to indicate that the companys market value can rise significantly as its lead development drug, PTB, progresses through its clinical study journey, which has just begun. 